Este sitio web utiliza cookies propias y de terceros para el correcto funcionamiento y visualización del sitio web por parte del usuario, así como para las estadísticas. Si continúa navegando, consideramos que acepta su uso. Por más información lea nuestros Términos y Condiciones

Addressing the Barriers to Pediatric Drug Development

Detalles
Cant. Págs.
64
Dimensiones
152 x 229 x 4.03mm | 109g
Fecha de publicación
Editorial
NATIONAL ACADEMIES PRESS
País de publicación
United_States
Lenguaje
English
ISBN
9780309107426
Precio de venta
$ 1.150
Aceptamos transferencia bancaria, Abitab, RedPagos y todas las tarjetas a través de mercadopagos.
Chateanos por WhatsApp
Precio de venta
$ 1.150
Aceptamos transferencia bancaria, Abitab, RedPagos y todas las tarjetas a través de mercado pagos.
Chateanos por WhatsApp
Detalles
Cant. Págs.
64
Dimensiones
152 x 229 x 4.03mm | 109g
Fecha de publicación
Editorial
NATIONAL ACADEMIES PRESS
País de publicación
United_States
Lenguaje
English
ISBN
9780309107426
Descripción

Decades of research have demonstrated that children do not respond to medications in the same way as adults. Differences between children and adults in the overall response to medications are due to profound anatomical, physiological, and developmental differences. Although few would argue that children should receive medications that have not been adequately tested for safety and efficacy, the majority of drugs prescribed for children50 to 75 percenthave not been tested in pediatric populations. Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence. Addressing the Barriers to Pediatric Drug Development is the summary of a workshop, held in Washington, on June 13, 2006, that was organized to identify barriers to the development and testing of drugs for pediatric populations, as well as ways in which the system can be improved to facilitate better treatments for children.